Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 2, 2004, Pages 195-203

  Yu, Rosie Z ^a   Geary, Richard S ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotide; Bioanalytical methods; Capillary gel electrophoresis; Enzyme linked immunosorbent assay; Hybridization; Mass spectrometry; Pharmacokinetic; Pharmacokinetic pharmacodynamic

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; TRACER;

DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYBRIDIZATION; INTERMETHOD COMPARISON; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REVIEW; VALIDATION STUDY; ANIMAL; BIOAVAILABILITY; DRUG SCREENING; HUMAN; METHODOLOGY; SENSITIVITY AND SPECIFICITY; STANDARD;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG EVALUATION; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; SENSITIVITY AND SPECIFICITY;

EID: 16644402176     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM: Selective inhibition of mutant Ha-Ras mRNA expression by antisense oligonucleotides. J Biol Chem (1992) 267(28):19954-19962.
2. Bennett CF, Dean N, Ecker DJ, Monia BP: Pharmacology of antisense therapeutic agents - cancer and inflammation. In: Methods in Molecular Medicine: Antisense Therapeutics. Agrawal S (Ed), Humana Press Inc, Totowa, NJ, USA (1996):13-46.
3. Cowsert LM: In vitro and in vivo activity of antisense inhibitors of Ras: Potential for clinical development. Anticancer Drug Des (1997) 12(5):359-371.
4. Rudin CM, Holmund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary RS, Yu RZ, Kwoh JT et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-Raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res (2001) 7(5):1214-1220.
5. Sewell LK, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr AF: Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther (2002) 303(3):1334-1343. First report to define the elimination phase of ASO in human plasma using a high sensitivity hybridization-based ELISA method.
6. Agrawal S: Antisense oligonucleotides: A possible approach for chemotherapy of AIDS. Prospects for Antisense Nucleic Acid Therapy of Cancer and Aids. Wickstrom E (Ed), Wiley-Liss, New York, NY, USA (1991):143-158.
7. Crooke ST: Treatment of retinitis induced by cytomegalovirus using intravitreal fomivirsen (ISIS 2922). In: Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Wickstrom E (Ed), Marcel Dekker, New York, NY, USA (1998):353-361.
8. Crooke ST, Bennett CF: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol (1996) 36:107-129.
9. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-Raf kinase. Nat Med (1996) 2(6):668-675.
10. Yuen A, Advani R, Fisher G, Halsey J, Lum B, Geary R, Kwoh TJ, Holmlund JT, Dorr A, Sikic B: A phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C a, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. 36th American Society of Clinical Oncology Annual Meeting, New Orleans, LA, USA (2000):Abs 1802.
11. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS et al: Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2002) 8(3):679-683.
12. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE: Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 18(9):1812-1823.
13. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, Xie N, Wilcox D, Jacobson P, Frost L, Kroeger PE et al: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA (2002) 99(17):11357-11362.
14. Jansen B, Wadl H, Inoue SA, Trulzsch B, Selzer E, Duchene M, Eichler HG, Wolff K, Pehamberger H: Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res Dev (1995) 5(4):271-277.
15. Crooke ST: Basic principles of antisense therapeutics. In: Antisense Research and Applications: Handbook of Experimental Pharmacology. Crooke ST (Ed), Springer-Verlag, Berlin, Germany (1998):1-50.
16. Dean NM, Butler M, Monia BP, Manoharan M: Pharmacology of 2′-O-(2-methoxy)ethyl modified antisense oligonucleotides. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST (Ed), Marcel Dekker, New York, NY, USA (2001):319-338.
17. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD, Iversen PL: c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther (2000) 292(3):921-928.
18. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL: Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci (2002) 91(4):1009-1018.
19. Good L, Nielsen PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol (1998) 16(4):355-358.
20. Hartmann C, Weiner GJ, Krieg AM: CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA (1999) 96(16):9305-9310.
21. Koppelhus U, Nielsen PE: Cellular delivery of peptide nucleic acid (PNA). Adv Drug Delivery Rev (2003) 55(2):267-280.
22. Geary RS: Current assessment of PK/PD relationships for antisense therapeutics. World Congress of Pharmacy and Pharmaceutical Sciences, Nice, France (2002).
23. Geary RS, Henry SP, Grillone LR: Fomivirsen: Clinical pharmacology and potential drug interactions. Clin Pharmacokinet (2002) 41(4):255-260.
24. Bigelow JC, Chrin LR, Mathews LA, McCormack JJ: High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J Chromatogr (1990) 533:133-140.
25. Leeds JM, Graham MJ, Troung L, Cummins LL: Quantitation of phosphorothioate oligonucteotides in human plasma. Anal Biochem (1996) 235(1):36-43. A comprehensive analytical report using CGE for the analysis of ASO in plasma samples.
26. Geary RS, Matson J, Levin AA: A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem (1999) 274(2):241-248. A comprehensive analytical report using COS for the analysis of ASO in tissue samples.
27. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA: Pharmacokinetics of a tumor necrosis factor-α phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metab Dispos (2003) 31(11):1419-1428.
28. Lopes D, Mayer LD: Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemoter Pnarmacol (2002) 49(1):57-68.
29. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmcol (1994) 45(5):932-943.
30. 3H-labeled oligonucleotides. II. 3′,5′-Blocked oligonucleotides. Mol Pharmacol (1995) 47(3):636-646.
31. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther (1993) 267(3):1181-1190.
32. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther (1994) 269(1):89-94.
33. Agrawal S. Temsamani J, Galbraith W, Tang J: Pharmacokinetics of amisense oligonucleotides. Clin Pharmacokinet(1995) 28(1):7-16.
34. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (Gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol (1995) 49(7):929-939.
35. Agrawal S, Zhang R: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. In: Antisense Research and Application. Crooke ST (Ed), Springer-Verlag, Berlin, Germany (1998):525-543.
36. Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S: Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev (1998) 8(1):43-52.
37. Stuart DD, Kao GY, Allen TM: A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther (2000) 7(3):466-475.
38. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther (1995) 58(1):44-53.
39. Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA: Comparison of Pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci (2001) 90(2):182-193.
40. Yu RZ, Baker B, Chappell A, Geary RS, Chueng E, Levin AA: Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem (2002) 304(1):19-25. A comprehensive analytical report using the highly sensitive hybridization ELISA method for the analysis of ASO in plasma samples.
41. Tavitian B, Terrazzino S, Kuhnast B, Marzabal S, Stettler O, Dolle F, Deverre JR, Jobert A, Hinnen F, Bendriem B, Crouzel C, Di Giamberardino L: In vivo Imaging of oligonucleotides with positron emission tomography. Nat Med (1998) 4(4):467-471.
42. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, Nicklin PL: Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol (1997) 54(6):657-668.
43. Grundy JS, Yu RZ, Geary RS, Levin AA, Zhao S, Keyhani A, Piccirilli G: Comparative single-dose disposition of radiolabeled ISIS 104838 and ISIS 113715 in rat. Annual Meeting of American Association of Pharmaceutical Scientists, Toronto, Canada (2002).
44. Ogawa S, Brown HE, Okano H, Pfaff DW: Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept (1995) 59(2):143-149.
45. Chen SH, Qian M, Brennan JM, Gallo JM: Determination of antisense phoshorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-excnange high-performance liquid chromatography and capillary gel electrophoresis. J Chromatogr B Biomed Sci Appl (1997) 692(1):43-51.
46. Reyderman L, Stavchansky S: Determination of single-stranded oligodeoxynucleotides by capillary gel electrophoresis with laser induced fluorescence and on column derivatization. J Chromatagr A (1996) 755(2):271-280.
47. Bruenner BA, Yip TT, Hutchens TW: Quantitative analysis of oligonucleotides by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom (1996) 10(14):1797-1801.
48. Li Y, Tan B, Fitzgerald TJ, Beck SR, LJ YX, Geary RS, Cummins LL, Yu RZ: Quantitation analysis of phosphorothiate oligodeoxynucleotides (ISIS 1082) by LC-MS/MS. Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics. Chicago, IL, USA (2001).
49. Li Y, Tan B, Fitzgerald TJ, Beck SR, Li YX, Geary RS, Cummins LL, Yu RZ: Quantitation analysis of phosphorothiate oligodeoxynucleotides (ISIS 15839) by LC-MS/MS. Annual Meeting of American Association of Pharmaceutical Scientists, Denver, CO, USA (2001).
50. Xu K, Williams EA, Wong S, Miller KJ, Geary RS, Yu RZ: Quantitative analysis of antisense oligonucleotides by reversed-phase LC-MS/MS. The 51st ASMS Conference on Mass Spectrometry, Montreal, Canada (2003).
51. de Serres M, McNulty MJ, Christensen L, Zon G, Findlay JW: Development of a novel scintillation proximity competitive hybridization assay for the determination of phosphorothioate antisense oligonucleotide plasma concentrations in a toxicokinetic study. Anal Biochem (1996) 233(2):228-233.
52. Boutet V, Delaunay V, De Oliveira MC, Boquet D, Grognet JM, Grassi J, Deverre JR: Real-time monitoring of the hybridization reaction: Application to the quantification of oligonucleotides in biological samples. Biochem Biophys Res Commun (2000) 268(1):92-98.
53. Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, Monia B, Nemunaitis J: A phase I trial of H-Ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer (2001) 92(5):1265-1271.
54. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI: Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res (1999) 5(11):3357-3363.
55. Geary RS, Yu RZ, Leeds JM, Ushiro-Watanabe T, Henry SP, Levin AA, Templin MV: Pharmacokinetic properties in animals. In: Antisense Drug Technology: Principles, Strategies, and Applications. Crooke ST (Ed), Marcel Dekker Inc. New York, NY, USA (2001):119-154.
56. Leeds JM, Henry SP, Bistner S, Scherrill S, Williams K, Levin AA: Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos (1998) 26(7):670-675.
57. Leeds JM, Henry SP, Geary RS, Burckin T, Levin AA: Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev (2000) 10(6):435-441.
58. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME: Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther (2001) 298(3):934-940.
59. Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ: Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-Raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol (1999) 17(7):2227-2236.
60. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J Clin Oncol (1999) 17(11):3586-3595.
61. Peng B, Andrews J, Nestorov I, Brennan B, Nicklin P, Rowland M: Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev (2001) 11(1):15-27.
62. Cohen AS, Bourque AJ, Wang BH, Smisek DL, Belenky A: A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev (1997) 7(1):13-22.
63. Gaus HJ, Owens SR, Winniman M, Cooper S, Cummins LL: On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem (1997) 69(3):313-319.
64. Griffey RH, Greig MJ, Gaus HJ, Liu K, Monteith D, Winniman M, Cummins LL: Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospray tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J Mass Spectrom (1997) 32(3):305-313.